JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Tange, Shoichiro ^a   Oktyabri, Dulamsuren ^a   Terashima, Minoru ^a   Ishimura, Akihiko ^a   Suzuki, Takeshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; MICRORNA 200; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN H3K27; PROTEIN JARID2; PROTEIN ZEB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HISTONE; JARID2 PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN;

ARTICLE; CANCER CELL LINE; CDH1 GENE; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REPRESSOR GENE; TRANSCRIPTION REGULATION; COLON TUMOR; GENETICS; HT 29 CELL LINE; LUNG TUMOR; METABOLISM;

CADHERINS; COLONIC NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONES; HT29 CELLS; HUMANS; LUNG NEOPLASMS; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; TRANSFORMING GROWTH FACTOR BETA;

EID: 84919917039     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115684     Document Type: Article

References (36)

1. Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13: 343-357.
2. Kooistra SM, Helin K (2012) Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13: 297-311.
3. Suzuki T, Terashima M, Tange S, Ishimura A (2013) Roles of histone methyl-modifying enzymes in development and progression of cancer. Cancer Sci 104: 795-800.
4. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, et al. (2002) New genes involved in cancer identified by retroviral tagging. Nat Genet 32: 166-174.
5. Suzuki T, Minehata K, Akagi K, Jenkins NA, Copeland NG (2006) Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice. Embo J 25: 3422-3431.
6. Yoshida M, Ishimura A, Terashima M, Enkhbaatar Z, Nozaki N, et al. (2011) PLU1 histone demethylase decreases the expression of KAT5 and enhances the invasive activity of the cells. Biochem J 437: 555-564.
7. Enkhbaatar Z, Terashima M, Oktyabri D, Tange S, Ishimura A, et al. (2013) KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle 12: 2100-2112.
8. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
9. Miyazono K, Ehata S, Koinuma D (2012) Tumor-promoting functions of transforming growth factor-beta in progression of cancer. Ups J Med Sci 117: 143-152.
10. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428.
11. Wu CY, Tsai YP, Wu MZ, Teng SC, Wu KJ (2012) Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet.
12. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, et al. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274-7284.
13. Lin T, Ponn A, Hu X, Law BK, Lu J (2010) Requirement of the histone demethylase LSD1 in Snai1- mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 29: 4896-4904.
14. Herz HM, Shilatifard A (2010) The JARID2-PRC2 duality. Genes Dev 24: 857-861.
15. Margueron R, Reinberg D (2011) The Polycomb complex PRC2 and its mark in life. Nature 469: 343-349.
16. Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, et al. (2009) Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139: 1290-1302.
17. Shen X, Kim W, Fujiwara Y, Simon MD, Liu Y, et al. (2009) Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 139: 1303-1314.
18. Pasini D, Cloos PA, Walfridsson J, Olsson L, Bukowski JP, et al. (2010) JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 464: 306-310.
19. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, et al. (2010) Jarid2 and PRC2, partners in regulating gene expression. Genes Dev 24: 368-380.
20. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
21. Chase A, Cross NC (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618.
22. Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N, Nozaki N (2008) The organization of histone H3 modifications as revealed by a panel of specific monoclonal antibodies. Cell Struct Funct 33: 61-73.
23. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z (2005) TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 6: 56.
24. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
25. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907.
26. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, et al. (2011) Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31: 2062-2074.
27. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, et al. (2011) Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20: 187-199.
28. Ke XS, Qu Y, Cheng Y, Li WC, Rotter V, et al. (2010) Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics 11: 669.
29. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, et al. (2011) miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10: 4256-4271.
30. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726.
31. Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, et al. (2012) Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol 87: 245-250.
32. Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, et al. (2014) JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 33: 1148-1157.
33. Scheel C, Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22: 396-403.
34. Cifuentes-Rojas C, Hernandez AJ, Sarma K, Lee JT (2014) Regulatory Interactions between RNA and Polycomb Repressive Complex 2. Mol Cell.
35. da Rocha ST, Boeva V, Escamilla-Del-Arenal M, Ancelin K, Granier C, et al. (2014) Jarid2 Is Implicated in the Initial Xist-Induced Targeting of PRC2 to the Inactive X Chromosome. Mol Cell 53: 301-316.
36. Kaneko S, Bonasio R, Saldana-Meyer R, Yoshida T, Son J, et al. (2014) Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. Mol Cell 53: 290-300.